StageZero Life Sciences Ltd
TSX:SZLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (3), the stock would be worth CA$0.03 (17% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.6 | CA$0.04 |
0%
|
| 3-Year Average | 3 | CA$0.03 |
-17%
|
| 5-Year Average | 3 | CA$0.03 |
-16%
|
| Industry Average | 81.1 | CA$0.91 |
+2 178%
|
| Country Average | 2.9 | CA$0.03 |
-18%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
StageZero Life Sciences Ltd
TSX:SZLS
|
4.9m CAD | 3.6 | -2.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 6.8 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 6.1 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 5.8 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 8.3 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 3.5 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 10.4 | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 3.3 | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 2.9 |
| 70th Percentile | 5.7 |
| Max | 15 639 353.3 |
Other Multiples
StageZero Life Sciences Ltd
Glance View
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. The company is headquartered in Richmond Hill, Ontario and currently employs 80 full-time employees. The firm has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. The firm offers ColonSentry product, which is a blood test to determine an individual’s current risk for having colorectal cancer. The company offers Aristotle, a mRNA-based multi-cancer detection panel for simultaneously screening of various cancers from a single sample of blood. In addition, the Company offers various COVID-19 tests, including polymerase chain reaction (PCR) tests and antibody tests. Its PCR tests can detect COVID-19 nucleic acid from patient nasopharyngeal swab specimens or saliva and are used to diagnose an active COVID-19 infection.
